These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 22864966)

  • 61. The behavioural effects of pramipexole, a novel dopamine receptor agonist.
    Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
    Eur J Pharmacol; 1997 Apr; 324(1):31-7. PubMed ID: 9137910
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D
    Düring SW; Nielsen MØ; Bak N; Glenthøj BY; Ebdrup BH
    Psychiatry Res; 2019 Apr; 274():58-65. PubMed ID: 30780063
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Antipsychotic combination using low-dose antipsychotics is as efficacious and safe as, but cheaper, than optimal-dose monotherapy in the treatment of schizophrenia: a randomized, double-blind study.
    Lin CH; Wang FC; Lin SC; Huang YH; Chen CC; Lane HY
    Int Clin Psychopharmacol; 2013 Sep; 28(5):267-74. PubMed ID: 23778382
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Sulpiride and melatonin decrease tinnitus perception modulating the auditolimbic dopaminergic pathway.
    Lopez-Gonzalez MA; Santiago AM; Esteban-Ortega F
    J Otolaryngol; 2007 Aug; 36(4):213-9. PubMed ID: 17942035
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pharmacology profile of F17464, a dopamine D
    Cosi C; Martel JC; Auclair AL; Collo G; Cavalleri L; Heusler P; Leriche L; Gaudoux F; Sokoloff P; Moser PC; Gatti-McArthur S
    Eur J Pharmacol; 2021 Jan; 890():173635. PubMed ID: 33065094
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Blonanserin extensively occupies rat dopamine D3 receptors at antipsychotic dose range.
    Baba S; Enomoto T; Horisawa T; Hashimoto T; Ono M
    J Pharmacol Sci; 2015 Mar; 127(3):326-31. PubMed ID: 25837930
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Duration of catalepsy correlates with increased intrastriatal sulpiride.
    Horikawa HP; Nakazato T; Hikosaka O
    Eur J Pharmacol; 1997 May; 326(1):15-21. PubMed ID: 9178650
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis: a reply.
    Lako IM; Liemburg EJ; Van den Heuvel ER; Knegtering H; Bruggeman R; Taxis K
    J Clin Psychopharmacol; 2014 Aug; 34(4):532-3. PubMed ID: 24949704
    [No Abstract]   [Full Text] [Related]  

  • 69. Using prepulse inhibition to detect functional D3 receptor antagonism: effects of WC10 and WC44.
    Weber M; Chang WL; Durbin JP; Park PE; Luedtke RR; Mach RH; Swerdlow NR
    Pharmacol Biochem Behav; 2009 Aug; 93(2):141-7. PubMed ID: 19426754
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Paliperidone ER versus risperidone for neurocognitive function in patients with schizophrenia: a randomized, open-label, controlled trial.
    Kim SW; Chung YC; Lee YH; Lee JH; Kim SY; Bae KY; Kim JM; Shin IS; Yoon JS
    Int Clin Psychopharmacol; 2012 Sep; 27(5):267-74. PubMed ID: 22809972
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The relationship between subjective well-being and dopamine D2 receptors in patients treated with a dopamine partial agonist and full antagonist antipsychotics.
    Mizrahi R; Mamo D; Rusjan P; Graff A; Houle S; Kapur S
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):715-21. PubMed ID: 19366489
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparing dopamine D(2) receptor occupancies for use in clinical practice: attractive proposition but fraught with pitfalls.
    Lee J; Takeuchi H; Remington G
    J Clin Psychopharmacol; 2014 Aug; 34(4):530-2. PubMed ID: 24875070
    [No Abstract]   [Full Text] [Related]  

  • 73. Effect of dopamine D2/D3 receptor antagonist sulpiride on amphetamine-induced changes in striatal extracellular dopamine.
    Jaworski JN; Gonzales RA; Randall PK
    Eur J Pharmacol; 2001 Apr; 418(3):201-6. PubMed ID: 11343690
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Intravenous Amisulpride for the Prevention of Postoperative Nausea and Vomiting: Two Concurrent, Randomized, Double-blind, Placebo-controlled Trials.
    Gan TJ; Kranke P; Minkowitz HS; Bergese SD; Motsch J; Eberhart L; Leiman DG; Melson TI; Chassard D; Kovac AL; Candiotti KA; Fox G; Diemunsch P
    Anesthesiology; 2017 Feb; 126(2):268-275. PubMed ID: 27902493
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia.
    Kapur S; Remington G
    Annu Rev Med; 2001; 52():503-17. PubMed ID: 11160792
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.
    Rüther E; Degner D; Munzel U; Brunner E; Lenhard G; Biehl J; Vögtle-Junkert U
    Pharmacopsychiatry; 1999 Jul; 32(4):127-35. PubMed ID: 10505482
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Augmentation with sulpiride for a schizophrenic patient partially responsive to clozapine.
    Stubbs JH; Haw CM; Staley CJ; Mountjoy CQ
    Acta Psychiatr Scand; 2000 Nov; 102(5):390-3; discussion 393-4. PubMed ID: 11098812
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sulpiride-induced tardive dystonia.
    Miller LG; Jankovic J
    Mov Disord; 1990; 5(1):83-4. PubMed ID: 1967484
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Low-dose risperidone augmentation of antidepressants in nonpsychotic depressive disorders with suicidal ideation.
    Viner MW; Chen Y; Bakshi I; Kamper P
    J Clin Psychopharmacol; 2003 Feb; 23(1):104-6. PubMed ID: 12544386
    [No Abstract]   [Full Text] [Related]  

  • 80. Dopamine D₃ receptor antagonism--still a therapeutic option for the treatment of schizophrenia.
    Gross G; Wicke K; Drescher KU
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Feb; 386(2):155-66. PubMed ID: 23128852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.